Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.
Sermonix Pharmaceuticals, a US-based biopharmaceutical company focused on metastatic breast and gynaecological cancers, has completed a $40m series A3 round led by Perceptive Advisors’ Xontogeny Ventures Fund II. The round included unnamed existing backers. Sermonix, which is based on research at Duke University, previously disclosed $26m in series A financing led by the Wild Family Office, with participation from private investors, in July 2019. The spinout had already raised nearly $1.6m in funding in July 2016, according to a regulatory…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
